PharmaCyte Biotech Inc (PMCB)

[1234jklm]

“ to ensure that the end-products of these manufacturing runs will convert the cancer prodrug ifosfamide into its cancer-killing form as well as they should.“


The ‘optimisation’ would seem to be because the cells when grown are not triggering the chemo as well as they should.’’ Or not all of them.

Something in the manufacturing process is changing the nature and thereby the efficacy of the cells imho. It’s got something to do with the way the cells are growing before and after encapsulation which makes them not exactly the same.

So it’s something they need to fix because if the cells aren’t exactly the same every time, then the fda won’t approve it.

They think they can fix it.

But to establish it, they will need to repeat lengthy testing of cells again and maybe twice.